The US Food and Drug Administration (FDA) on Monday finalized guidance to assist in the clinical development of treatments for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.

ALS is a very severe neurodegenerative disease in which nerve cells in the spinal cord controlling muscles and movement slowly die. There is no effective treatment and the average life expectancy ...

Acting US Food and Drug Administration (FDA) Commissioner Ned Sharpless on Thursday announced that the agency would finalize guidance on developing treatments for amyotrophic lateral sclerosis (ALS) ...

Athira Pharma, Inc. has announced favorable results from a Phase 1 clinical trial of its drug candidate ATH-1105, which targets neurodegenerative diseases like amyotrophic lateral sclerosis (ALS). The ...

One night in November 2018, I fell while crossing a street in Subic Bay, a U.S. naval logistics station in The Philippines. My face whacked the asphalt. Lying in the path of oncoming traffic, I couldn ...

Degradation of motor neurons, conceptual computer illustration. Motor neuron diseases are a group of neurodegenerative disorders Amyotrophic lateral sclerosis (ALS) is the most common of the motor ...

People who had a history of a traumatic head injury were nearly 50% more likely than those without head injury to have an ALS diagnosis, researchers found. However, multiple head ...